Accessibility Menu
Cosmo logo

Cosmo(OTC) CMOPF

Market Cap$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-55%
5 Year-9%
1 Year-2%
1 Month-7%
$72.04
-1.32%
-0.96Today
Cosmo last closing stock price
MetricPriceDate
Last closeUSD 72.042026-08-21
Cosmo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.04%USD 75.072026-08-14
1 month-6.6%USD 77.132026-07-22
3 month-28.05%USD 100.132026-05-22
Year to date-44.65%USD 130.152025-12-31
1 year-1.84%USD 73.392025-07-30
3 year+56.12%USD 46.142023-06-07
5 year-9.42%USD 79.542021-08-20
Since inception-55.17%USD 160.682017-07-31

Cosmo Financials at a Glance

Market Cap

$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€284.67M

Net Income (TTM)

€48.92M

EPS (TTM)

-$0.44

P/E Ratio

-162.95

Dividend

$2.46

Beta (Volatility)

0.17 (Low)

Price

$72.04

Volume

105

Open

$72.16

Previous Close

$72.04

Daily Range

$72.04 - $72.16

52-Week Range

$69.71 - $169.90

Estimated Earnings Date

Mar 24, 2027

CMOPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosmo

Cosmo Pharmaceuticals N.V. is a life sciences company focused on developing and manufacturing innovative pharmaceuticals for gastroenterology, dermatology, and health technology. Headquartered in Dublin, Ireland, the company leverages advanced technologies, including artificial intelligence, to enhance patient care and treatment outcomes.

Products and Services
  • GI Genius: AI-assisted system for real-time detection of colorectal lesions
  • Winlevi: Prescription medication for treating acne vulgaris
  • Lialda: Once-daily mesalamine tablet for ulcerative colitis remission
Growth Outlook
  • Strong pipeline with multiple products in various clinical trial phases
  • Expansion into new markets expected to drive revenue growth
  • Increased focus on AI technology in healthcare enhances competitive edge
Financial Highlights
  • Recent quarterly revenue of 49.87 million EUR, showing resilience
  • Trailing twelve months (TTM) gross profit margin at 45.52%
  • Cash and short-term investments totaling 194.19 million EUR, indicating strong liquidity
Cosmo Pharmaceuticals N.V. is positioned in a growing sector with a diverse product portfolio aimed at addressing significant medical needs. The company's innovative approach, particularly in utilizing AI technology, sets it apart in the pharmaceutical landscape. Recent financial performance reflects a solid revenue base and healthy gross profit margins, suggesting operational efficiency. With a robust pipeline and strategic market expansion plans, Cosmo Pharmaceuticals presents a compelling opportunity for potential investors interested in the healthcare sector.
AI Generated • Aug 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

324.5

CEO

Giovanni di Napoli, MBA

Website

www.cosmopharma.com

Headquarters

Dublin, DU D02 KV60, IE

CMOPF Financials

Key Financial Metrics (TTM)

Gross Margin

45.52%

Operating Margin

-13.37%

Net Income Margin

-6.18%

Return on Equity

-1.21%

Return on Capital

-2.16%

Return on Assets

-0.91%

Earnings Yield

-0.61%

Dividend Yield

3.42%

Payout Ratio

-6.93%

Stock Overview

Market Cap

$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.19M

Volume

105

Avg. Volume

264.159

Financials (TTM)

Gross Profit

€206.59M

Operating Income

€46.84M

EBITDA

€75.69M

Operating Cash Flow

€44.09M

Capital Expenditure

-€10.57M

Free Cash Flow

€33.52M

Cash & ST Invst.

€194.19M

Total Debt

€4.30M

Cosmo Performance Analysis

Cosmo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 107,292,91739.5%
20232023-12-31EUR 100,305,906-6.5%
20242024-12-31EUR 288,582,113187.7%
20252025-12-31EUR 117,568,479-59.3%
Cosmo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-4.2%
Q22025-06-30-60.4%
Q42025-12-311.6%
Q22026-06-30-5.0%
Cosmo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 1.10-27.3%
20232023-12-31EUR -0.72N/A
20242024-12-31EUR 8.78N/A
20252025-12-31EUR -0.26N/A
Cosmo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-27.2%
Q22025-06-30-103.8%
Q42025-12-3123.1%
Q22026-06-30-180.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€49.87M

-63.4%

Gross Profit

€22.17M

-80.4%

Gross Margin

44.45%

N/A

Market Cap

$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.82M

N/A

Employees

324

N/A

Net Income

-€4.72M

-106.2%

EBITDA

-€2.81M

-103.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€194.19M

+45.6%

Total Debt

€4.30M

+195.8%

Accounts Receivable

€36.49M

+54.3%

Inventory

€13.42M

-3.5%

Long Term Debt

€3.58M

+401.3%

Short Term Debt

€724.18K

-2.3%

Return on Assets

-0.91%

N/A

Return on Invested Capital

-2.05%

N/A

Free Cash Flow

-€9.50M

-109.7%

Operating Cash Flow

-€7.34M

-107.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EVOTFEvotec SE
$6.69+0.00%
LJUIFSSY Group Limited
$0.40+0.00%
GNTLFGenetic Technologies Limited
$1.00+0.00%
NPPNYNippon Shinyaku Co., Ltd.
$5.61+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.60-0.01%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.03+0.02%
IBITiShares Bitcoin Trust
$43.68+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.17+0.01%

Questions About CMOPF

What is the current price of Cosmo?

Cosmo is trading at $72.04 per share.

What is the 52-week range for Cosmo?

Over the past 52 weeks, Cosmo has traded between $69.71 and $169.90.

How much debt does Cosmo have?

As of the most recent reporting period, Cosmo reported total debt of €5.01M.

How much cash does Cosmo have on hand?

Cosmo reported €65.61M in cash and cash equivalents in its most recent financial results.

What is Cosmo’s dividend yield?

Cosmo currently has a dividend yield of 3.42%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services